Free Trial

Alector (ALEC) Competitors

$5.39
-0.02 (-0.37%)
(As of 05/21/2024 ET)

ALEC vs. ADPT, TSHA, LXEO, TCRX, OCGN, EXAI, VALN, ALLO, VYGR, and EDIT

Should you be buying Alector stock or one of its competitors? The main competitors of Alector include Adaptive Biotechnologies (ADPT), Taysha Gene Therapies (TSHA), Lexeo Therapeutics (LXEO), TScan Therapeutics (TCRX), Ocugen (OCGN), Exscientia (EXAI), Valneva (VALN), Allogene Therapeutics (ALLO), Voyager Therapeutics (VYGR), and Editas Medicine (EDIT). These companies are all part of the "biological products, except diagnostic" industry.

Alector vs.

Adaptive Biotechnologies (NASDAQ:ADPT) and Alector (NASDAQ:ALEC) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, risk, media sentiment, valuation, community ranking, profitability, analyst recommendations, earnings and dividends.

In the previous week, Alector had 1 more articles in the media than Adaptive Biotechnologies. MarketBeat recorded 3 mentions for Alector and 2 mentions for Adaptive Biotechnologies. Adaptive Biotechnologies' average media sentiment score of 1.28 beat Alector's score of 0.94 indicating that Alector is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Adaptive Biotechnologies
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Alector
1 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Adaptive Biotechnologies has a beta of 1.27, meaning that its share price is 27% more volatile than the S&P 500. Comparatively, Alector has a beta of 0.82, meaning that its share price is 18% less volatile than the S&P 500.

Alector has lower revenue, but higher earnings than Adaptive Biotechnologies. Alector is trading at a lower price-to-earnings ratio than Adaptive Biotechnologies, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Adaptive Biotechnologies$170.28M3.02-$225.25M-$1.49-2.34
Alector$97.06M5.35-$130.39M-$1.38-3.91

99.2% of Adaptive Biotechnologies shares are held by institutional investors. Comparatively, 85.8% of Alector shares are held by institutional investors. 6.2% of Adaptive Biotechnologies shares are held by company insiders. Comparatively, 14.0% of Alector shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Alector received 55 more outperform votes than Adaptive Biotechnologies when rated by MarketBeat users. Likewise, 60.58% of users gave Alector an outperform vote while only 56.52% of users gave Adaptive Biotechnologies an outperform vote.

CompanyUnderperformOutperform
Adaptive BiotechnologiesOutperform Votes
91
56.52%
Underperform Votes
70
43.48%
AlectorOutperform Votes
146
60.58%
Underperform Votes
95
39.42%

Adaptive Biotechnologies currently has a consensus target price of $6.80, indicating a potential upside of 94.84%. Alector has a consensus target price of $14.00, indicating a potential upside of 159.74%. Given Adaptive Biotechnologies' higher probable upside, analysts clearly believe Alector is more favorable than Adaptive Biotechnologies.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Adaptive Biotechnologies
0 Sell rating(s)
2 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.67
Alector
1 Sell rating(s)
1 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.57

Adaptive Biotechnologies has a net margin of -123.24% compared to Adaptive Biotechnologies' net margin of -125.11%. Alector's return on equity of -56.58% beat Adaptive Biotechnologies' return on equity.

Company Net Margins Return on Equity Return on Assets
Adaptive Biotechnologies-123.24% -56.58% -27.45%
Alector -125.11%-71.80%-18.28%

Summary

Alector beats Adaptive Biotechnologies on 11 of the 18 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ALEC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ALEC vs. The Competition

MetricAlectorBiological Products IndustryMedical SectorNASDAQ Exchange
Market Cap$519.54M$2.99B$5.05B$8.01B
Dividend YieldN/A2.18%2.79%3.91%
P/E Ratio-3.9113.34129.7415.08
Price / Sales5.35316.342,437.4277.68
Price / CashN/A170.3932.6930.67
Price / Book3.825.745.494.66
Net Income-$130.39M-$46.33M$104.09M$213.44M
7 Day Performance-4.60%-1.39%0.26%0.46%
1 Month Performance4.26%9.18%4.09%5.46%
1 Year Performance-29.73%1.18%4.85%8.75%

Alector Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ADPT
Adaptive Biotechnologies
3.7391 of 5 stars
$3.49
-2.8%
$6.80
+94.8%
-44.4%$514.32M$170.28M-2.34709
TSHA
Taysha Gene Therapies
2.0753 of 5 stars
$2.89
-6.5%
$7.00
+142.2%
+290.8%$540.49M$15.45M-5.9052Gap Up
LXEO
Lexeo Therapeutics
2.0665 of 5 stars
$15.00
+8.9%
$20.80
+38.7%
N/A$494.10M$650,000.00-0.6758News Coverage
High Trading Volume
TCRX
TScan Therapeutics
2.1627 of 5 stars
$9.28
+1.0%
$12.00
+29.3%
+190.0%$490.57M$14.81M-7.25154
OCGN
Ocugen
0.7256 of 5 stars
$1.85
-3.6%
$4.67
+152.3%
+174.6%$476.06M$6.04M-7.4065Analyst Revision
EXAI
Exscientia
1.5051 of 5 stars
$4.70
-9.4%
$9.75
+107.4%
-22.2%$568.18M$25.60M-3.18483
VALN
Valneva
1.1075 of 5 stars
$8.26
-6.6%
$21.67
+162.3%
-32.2%$575.21M$152.96M-20.15676Gap Down
ALLO
Allogene Therapeutics
3.2554 of 5 stars
$2.69
+3.9%
$9.80
+264.3%
-55.8%$459.59M$90,000.00-1.50232Analyst Forecast
Insider Buying
Analyst Revision
News Coverage
Gap Up
VYGR
Voyager Therapeutics
3.7927 of 5 stars
$8.44
-0.1%
$18.00
+113.3%
-35.9%$459.05M$250.01M-168.77162Analyst Revision
EDIT
Editas Medicine
3.6961 of 5 stars
$5.51
-0.2%
$13.90
+152.3%
-40.9%$453.14M$78.12M-2.62265Gap Up

Related Companies and Tools

This page (NASDAQ:ALEC) was last updated on 5/22/2024 by MarketBeat.com Staff

From Our Partners